ReviewFrontiers in medicine2026
Roles and molecular mechanisms of EMILIN-1 in physiology and disease: a narrative review.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elastin microfibril interface located protein 1 (EMILIN-1) is a homotrimeric glycoprotein of the extracellular matrix (ECM) family that participates in ECM organization and regulates cell signaling. It is critical for maintaining tissue homeostasis, intercellular communication, and modulation of pathological microenvironments. Accumulating evidence indicates that the development and progression of various human diseases, including chronic inflammatory diseases, lymphatic diseases, and cancers, are closely associated with abnormal expression or dysfunction of EMILIN-1. Remarkably, the biological effects of EMILIN-1 are highly context dependent and cell type dependent. EMILIN-1 acts as a well-recognized tumor suppressor in malignancies such as head and neck squamous cell carcinoma and breast cancer, yet it promotes lymphatic disease progression through modulation of transforming growth factor β (TGF-β) signaling. This review summarizes the molecular structural characteristics, physiological functions, and major regulatory pathways of EMILIN-1, with particular emphasis on functional heterogeneity and the underlying mechanisms across diverse diseases. We also highlight recent advances in clinical translation, followed by a discussion of current research bottlenecks and prospective directions. These insights establish a theoretical framework for developing diagnostic biomarkers and optimizing targeted therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.